A PHASE I, MULTICENTER DOSE-ESCALATION STUDY TO ASSESS THE TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ANTI-TUMOR ACTIVITY OF AZD5153 IN PATIENTS WITH RELAPSED/REFRACTORY MALIGNANT SOLID TUMORS, INCLUDING LYMPHOMAS

Registry ID

D6520C00001

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

ASTRAZENECA CANADA INC

Start date

2020-07-07

Completion date

2020-07-14

Last update

2018-11-23

Conditions

• RELAPSED OR REFRACTORY SOLID TUMORS

Related clinical trials

• A PHASE I STUDY OF GCAR1, A CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY FOR PARTICIPANTS WITH SELECTED RELAPSED/REFRACTORY GPNMB-EXPRESSING SOLID TUMOURS
• PHASE I/II STUDY OF SILMITASERTIB (CX-4945) IN COMBINATION WITH CHEMOTHERAPY IN CHILDREN AND YOUNG ADULTS WITH RELAPSED REFRACTORY SOLID TUMORS
• A PHASE I-II, FIRST-IN-HUMAN STUDY OF SKB264 IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE /METASTATIC SOLID TUMORS WHO ARE REFRACTORY TO AVAILABLE STANDARD THERAPIES.
• A PHASE 1/ 2 STUDY OF BAY 1895344 (ELIMUSERTIB, IND#152153, NSC#810486) IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY SOLID TUMORS
• A PHASE I/II STUDY OF NERATINIB IN PEDIATRIC PATIENTS WITH RELAPSED/ REFRACTORY SOLID TUMORS

View on source registry